With new data, UBI Asia hoping for review of vaccine EUA application

Taiwan-based United Biomedical Inc. (UBI) Asia is planning to reapply for emergency use authorization (EUA) for its COVID-19 vaccine based on what it described as very strong data after giving clinical trial subjects a third dose of the vaccine.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)